Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 95NIH 7NETWORK 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myasthenia Gravis 3Leukemia 3Myelodysplastic Syndromes 2Lymphoma 2Graft vs Host Disease 2Thymic aplasia 1Skin Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Erectile Dysfunction 1Dermatitis, Atopic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 17blinatumomab 16fludarabine 13Vincristine 11Cytarabine 10tisagenlecleucel 8pegaspargase 8nilotinib 8Methotrexate 8Inotuzumab Ozogamicin 8Clofarabine 8venetoclax 7Dexamethasone 7asparaginase erwinia chrysanthemi recombinant 6Dasatinib 6Azacitidine 5AP 1903 reagent 5aflibercept 4Mercaptopurine 4Imatinib Mesylate 4Filgrastim 4Etoposide 4Drug Therapy 4Daunorubicin 4ponatinib 3Sensitivity and Specificity 3Mitoxantrone 3Immunotherapy, Adoptive 3Granulocyte Colony-Stimulating Factor 3CPX-351 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Tacrolimus × Clear all
NCT04095858 2023-02-08

CATHY

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
11 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡